mogamulizumab

Home
Ligands
mogamulizumab

GtoPdb Ligand ID: 6477

Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®

mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))

Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

No information available.

No information available.

Summary of Clinical Use
Approved first in Japan, for the treatment of relapsed or refractory adult T cell leukemia/lymphoma. The 2018 EMA and FDA approvals allow Poteligeo® to be used as a treatment for two rare cutaneous T cell lymphomas; relapsed or refractory mycosis fungoides or Sézary syndrome (following at least one prior systemic therapy). In Europe the drug has EMA orphan designation for the treatment of cutaneous and peripheral T cell lymphomas.

Summary of Clinical Use

Approved first in Japan, for the treatment of relapsed or refractory adult T cell leukemia/lymphoma. The 2018 EMA and FDA approvals allow Poteligeo® to be used as a treatment for two rare cutaneous T cell lymphomas; relapsed or refractory mycosis fungoides or Sézary syndrome (following at least one prior systemic therapy). In Europe the drug has EMA orphan designation for the treatment of cutaneous and peripheral T cell lymphomas.

Mechanism Of Action and Pharmacodynamic Effects
Targets CCR4 on immunosuppressive T_reg cells that have been recruited to the tumour microenvironment by CCR4 ligands such as CCL17 and CCL22 which are produced by intratumoural dendritic cells and macrophages. The resulting reduction in T_reg suppression of T_eff cell activity facilitates improved immune cell-mediated tumour cell killing.

Mechanism Of Action and Pharmacodynamic Effects

Targets CCR4 on immunosuppressive T_reg cells that have been recruited to the tumour microenvironment by CCR4 ligands such as CCL17 and CCL22 which are produced by intratumoural dendritic cells and macrophages. The resulting reduction in T_reg suppression of T_eff cell activity facilitates improved immune cell-mediated tumour cell killing.

External links
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Drugs.com
European Medicines Agency (EMA)